Evidence map›Paper›PMID 29311658›Full record

ArticleScientific reports2018

Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer.

Jeenah Park, Scott Thomas, Allison Y Zhong, Alan R Wolfe, Gregor Krings, Manuela Terranova-Barberio, Nela Pawlowska, Leslie Z Benet, Pamela N Munster

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jeenah ParkDivision of Hematology and Oncology, University of California, San Francisco, USA.
Scott ThomasDivision of Hematology and Oncology, University of California, San Francisco, USA.
Allison Y ZhongDepartment of Molecular and Cell Biology, University of California, Berkeley, USA.
Alan R WolfeDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, USA.ORCID http://orcid.org/0000-0002-0932-4146
Gregor KringsDepartment of Pathology, University of California, San Francisco, USA.
Manuela Terranova-BarberioDivision of Hematology and Oncology, University of California, San Francisco, USA.
Nela PawlowskaDivision of Hematology and Oncology, University of California, San Francisco, USA.
Leslie Z BenetDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, USA.
Pamela N MunsterDivision of Hematology and Oncology, University of California, San Francisco, USA. pamela.munster@ucsf.edu.
University of California, San Francisco · USUniversity of California, Berkeley · US

Funding

The role of HDAC2 in hormone therapy resistanceR01CA152989 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUNSTER, PAMELA N. · 2011 to 2015
$1.6M
NCI NIH HHS R01 CA152989
6 · The paper itself

Abstract

Broad use of germline testing has identified an increasing number of women at risk for breast cancer with a need for effective chemoprevention. We report a novel method to selectively deliver various anti-estrogens at high drug levels to the breast tissue by implanting a device comprised of silastic tubing. Optimized tubing properties allow elution of otherwise poorly bioavailable anti-estrogens, such as fulvestrant, into mammary tissue in vitro and in vivo with levels sufficient to inhibit estrogen receptor activation and tumor cell proliferation. Implantable silastic tubing delivers fulvestrant selectively to mouse mammary fat tissue for one year with anti-tumor effects similar to those achieved with systemic fulvestrant exposure. Furthermore, local delivery of fulvestrant significantly decreases cell proliferation, as assessed by Ki67 expression, most effectively in tumor sections adjacent to tubing. This approach may thereby introduce a potential paradigm shift and offer a promising alternative to systemic therapy for prevention and early interception of breast cancer.

Indexed as

ChemopreventionAnimalsAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsCell Line, TumorCell ProliferationChromatography, LiquidDisease Models, AnimalEstradiolEstrogen Receptor ModulatorsFemaleFulvestrantGerm-Line MutationHumansTandem Mass SpectrometryAntineoplastic Agents, HormonalBiomarkers, TumorEstradiolEstrogen Receptor ModulatorsFulvestrant

Identifiers

PMID29311658
PMCPMC5758798
OpenAlexW2781954335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.